Zoetis Inc. (NYSE:ZTS) Shares Sold by William Allan Corp

William Allan Corp lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 46.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,410 shares of the company’s stock after selling 13,482 shares during the quarter. Zoetis makes up about 1.5% of William Allan Corp’s holdings, making the stock its 27th biggest position. William Allan Corp’s holdings in Zoetis were worth $2,511,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of ZTS. AMF Tjanstepension AB increased its position in shares of Zoetis by 23.4% during the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new position in Zoetis during the third quarter worth approximately $59,000. CWM LLC lifted its stake in Zoetis by 1.8% in the third quarter. CWM LLC now owns 19,330 shares of the company’s stock valued at $3,777,000 after buying an additional 339 shares during the last quarter. Wedmont Private Capital boosted its holdings in shares of Zoetis by 15.1% in the third quarter. Wedmont Private Capital now owns 2,958 shares of the company’s stock valued at $554,000 after acquiring an additional 388 shares during the period. Finally, Enterprise Bank & Trust Co acquired a new position in shares of Zoetis in the 3rd quarter valued at $208,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $174.07 on Friday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a market cap of $78.54 billion, a price-to-earnings ratio of 32.72, a PEG ratio of 2.72 and a beta of 0.90. The firm has a 50 day moving average of $169.39 and a 200-day moving average of $179.32.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the firm posted $1.36 EPS. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, equities analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s payout ratio is currently 37.59%.

Analyst Ratings Changes

A number of analysts recently weighed in on ZTS shares. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley lowered their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Finally, Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.